Phase 3 N=114 Irbesartan and Atenolol in Hypertensive Heart Disease
Hypertension
Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=14,986 Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany
Arterial Hypertension
Primary: Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP) — 11.8; 9.7; 9.9 percent change
N/A N=718 Azilsartan Circadian and Sleep Pressure
Hypertension
Primary: Change in Nocturnal Systolic Blood Pressure Level — -12.6; -17.5 mmHg
Phase 3 N=261 Obese Hypertension Study (0954-315)
Hypertension
Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg
N/A N=92 Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Systemic Arterial Hypertension · Hypertension Resistant to Conventional Therapy · Myocardial Infarction
Primary: Strokes, Either Fatal or Nonfatal — 24; 7 participants — p=0.19
Phase 2 N=53 The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial
Cognitive Impairment · Hypertension · Aging
Primary: Cognitive Assessment: Trail Making Test Part B — -14; 17; 4 seconds — p=0.008
Phase 4 N=201 LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
Hypertension
Primary: Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug — 0.28; -0.12 meters/second
Phase 3 N=27 Telmisartan+Amlodipine Fixed Dose Combination in Hypertension
Hypertension
Primary: DBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean — -12.76; -23.82 mmHg
N/A N=5 HIRREM for Stage 1 Primary Hypertension
Hypertension · Blood Pressure · Cardiovascular Diseases
Primary: Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device. — -3.00; -6.67; -6.00; -7.67 mmHg
Phase 2 N=14 The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension
Hypertension
Primary: Muscle Sympathetic Nerve Activity at Rest — 41; 43.8 bursts/minute
Phase 4 N=488 Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
Stage 2 Systolic Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure After 6 Weeks — 166.8; 168.5; 135.5; 142.5 mmHg
N/A N=1,247 The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension
Arterial Hypertension
Primary: The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline — 33.47 mm Hg
N/A N=533 A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan
Hypertension · Stroke
Primary: The Percentage of Hypertensive Patients Who Achieve Regulated BP Levels According to the ESC/ESH Guidelines, After They Have Been Treated With Eprosartan for 6 Months…
Phase 2 N=490 Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
Essential Hypertension
Primary: Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough — 97.5; 97.8; 97.7; 97.8 mmHg — p=<0.001
N/A N=1,342 International Registry for Ambulatory Blood Pressure and Arterial Stiffness Telemonitoring
Hypertension
Primary: 24-hour Pulse Wave Velocity (PWV) — 10.6 m/s
Phase 3 N=1,010 Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
Essential Hypertension
Primary: Change in Mean Trough Sitting Diastolic Blood Pressure — -11.16; -10.45 mm Hg — p=0.2648
Phase 3 N=142 Uric Acid and Hypertension in African Americans
Cardiovascular Diseases · Heart Diseases · Hypertension
Primary: Change in Diastolic Blood Pressure by Cuff 8-10 Weeks Minus Baseline — 3.44; -0.83 mm Hg — p=0.059
N/A N=100 GAstric Bypass to Treat obEse Patients With steAdy hYpertension
Systemic Hypertension · Obesity
Primary: Number of Participants With a Reduction in the Number of Anti-hypertensive Drugs Used and Maintaining Blood Pressure Below 140x90mmHg — 41; 6 Participants
N/A N=75 Understanding the Exercise-Hypertension Paradox
Hypertension
Primary: Blood Pressure — 103; 106; 94; 101 mmHg
Phase 3 N=2,204 Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension
Essential Hypertension
Primary: Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg — -6.1; -7.1; -8.9 mm Hg — p=0.1187
N/A N=2,913 Telmisartan Tab Hypertension
Hypertension
Primary: Percentage of Patients With Blood Pressure < 140/90 mm Hg — 69.6 Percentage of participants
N/A N=17 Controlling and Lowering Blood Pressure With The MOBIUSHD™
Hypertension
Primary: Adverse Events — 1; 1; 1; 1 participants
Phase 2 N=250 Treatment of Early Hypertension Among Persons Living With HIV in Haiti
HIV/AIDS · Pre Hypertension
Primary: Change in Mean Systolic Blood Pressure (SBP) — -10.58; -4.65 mmHg — p=<0.0001
Phase 4 N=233 Candesartan Effect in Second Stage Arterial Hypertension
Stage II Hypertension
Primary: Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy — -17.0; -14.1 mmHg
Phase 2 N=454 Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
Hypertension
Primary: Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks — -12.57; -8.90 mmHg — p=0.010
N/A N=167 Helius in Hypertension-I: The UK Hypertension Registry
Essential Hypertension
Primary: Frequency of Medication-taking (% Taking Adherence) — 75 percentage of taking adherence
Phase 3 N=858 Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
Hypertension
Primary: Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8 — -47.5; -36.9; -43.2 mmHg (millimeters of mercury) — p=<0.0001
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
Phase 2 N=59 Tissue Sodium in Pre-hypertensive Patients
Hypertension
Primary: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) — -0.202; 0.430; -1.745; -0.407 mmol/L
Phase 4 N=888 Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
Hypertension
Primary: Change From Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) to Week 7 — -28.5; -37.0 mmHg — p=<0.0001